Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Assets: 2010-2024

Historic Assets for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $139.3 million.

  • Altimmune's Assets rose 47.74% to $218.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.4 million, marking a year-over-year increase of 47.74%. This contributed to the annual value of $139.3 million for FY2024, which is 33.87% down from last year.
  • Per Altimmune's latest filing, its Assets stood at $139.3 million for FY2024, which was down 33.87% from $210.6 million recorded in FY2023.
  • Altimmune's Assets' 5-year high stood at $245.1 million during FY2020, with a 5-year trough of $139.3 million in FY2024.
  • Its 3-year average for Assets is $185.6 million, with a median of $206.9 million in 2022.
  • As far as peak fluctuations go, Altimmune's Assets surged by 353.43% in 2020, and later plummeted by 33.87% in 2024.
  • Over the past 5 years, Altimmune's Assets (Yearly) stood at $245.1 million in 2020, then dropped by 10.71% to $218.9 million in 2021, then declined by 5.45% to $206.9 million in 2022, then grew by 1.79% to $210.6 million in 2023, then slumped by 33.87% to $139.3 million in 2024.